Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

48.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 232
Open 48.04
Bid (Size) 48.04 (1)
Ask (Size) 48.88 (1)
Prev. Close 48.04
Today's Range 48.04 - 48.04
52wk Range 37.55 - 91.10
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks. 
Via The Motley Fool
Why We Buy Stocks
Is fear of missing out (FOMO) controlling your portfolio? 
Via The Motley Fool

Performance

YTD
-27.28%
-27.28%
1 Month
+2.78%
+2.78%
3 Month
-16.00%
-16.00%
6 Month
-14.84%
-14.84%
1 Year
+19.80%
+19.80%

More News

Read More
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is CRISPR Therapeutics Stock a Buy?
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
Via The Motley Fool
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
Via The Motley Fool
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Via The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
Via The Motley Fool
1 Biotech Stock Down 62% to Buy and Hold
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Looking for Stock Bargains With Room to Run? Try This.
Via The Motley Fool
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Got the Market Sell-Off Blues? Do These 3 Things Right Now
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Via The Motley Fool
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.